Id: acc2432
Group: 2sens
Protein: TOPK
Gene Symbol: PBK
Protein Id: Q96KB5
Protein Name: TOPK_HUMAN
PTM: phosphorylation
Site: Thr9
Site Sequence: -MEGISNFKTPSKLSEKKKSV
Disease Category: Cancer
Disease: Melanoma
Disease Subtype:
Disease Cellline: RPMI7951
Disease Info:
Drug: arsenite
Drug Info: -
Effect: modulate
Effect Info: As3+ treatment induces the phosphorylation of TOPK and histone H2AX in RPMI7951 human melanoma cells and induces apoptosis of human melanoma cells.
Note:
Score: 4.0
Pubmed(PMID): 17145805
Sentence Index:
Sentence:

Sequence & Structure:

MEGISNFKTPSKLSEKKKSVLCSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGEKSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKKLLHGDIKSSNVVIKGDFETIKICDVGVSLPLDENMTVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINLSNDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVCTNEDPKDRPSAAHIVEALETDV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PBK-Ser19
Cancer Intensity
BRCA 0.276
COAD
HGSC
ccRCC
GBM -1.462
HNSC 0.391
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.795
PBK-Ser32
Cancer Intensity
BRCA 0.9
COAD 0.061
HGSC -2.223
ccRCC
GBM 0.166
HNSC 0.449
LUAD 0.935
LUSC -0.366
non_ccRCC
PDAC
UCEC 0.078
PBK-Ser57
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.707
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
PBK-Ser59
Cancer Intensity
BRCA -0.23
COAD 0.115
HGSC 2.201
ccRCC
GBM 0.116
HNSC -0.136
LUAD -1.126
LUSC -0.139
non_ccRCC
PDAC -1.252
UCEC 0.452
PBK-Thr24
Cancer Intensity
BRCA
COAD 0.863
HGSC -1.096
ccRCC
GBM
HNSC 0.233
LUAD
LUSC
non_ccRCC
PDAC
UCEC
PBK-Thr26
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 9 U Squamous cell carcinoma Phosphorylation 29904102
T 9 U Non-small cell lung cancer Phosphorylation 33158479

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 7.9425 up
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK K562 Dasatinib 9.2207 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK HeLa Curcumin 5.8404 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK K562 Dasatinib 5.3382 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK K562 Dasatinib 11.0018 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK K562 Dasatinib 10.9939 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK K562 Imatinib 8.2143 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK KYSE-520 SHP099 8.1386 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK PC-9 Lapatinib 7.2216 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK PC-9 LapatinibAZD4547 5.2026 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK Ramos Rituximab -1.4686 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 9.1398 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 8.4336 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 7.1706 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 7.0867 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 7.5783 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 7.475 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK RPMI8226 BTZ 8.3491 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 Dasatinib 10.262 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Afatinib 7.6865 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Dasatinib 5.6133 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Dasatinib 5.5499 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Gefitinib 6.9595 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Imatinib 2 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 AZD8055 7.5202 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A549 Dactolisib 11.3818 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 Dactolisib 5.6411 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A431 Afatinib 6.511 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A549 MK2206 11.0267 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 MK2206 8.8081 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK A549 PD325901 11.1375 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 PD325901 6.0415 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 Refametinib 4.7886 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSKLSEK A549 Staursporin 7.2663 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK HeLa A485 6.0007 -
Q96KB5 PBK P Thr9 MEGISNFKT(ph)PSK HeLa A486 5.2568 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: